




Sangamo BioSciences, Inc. September 2009

- **Robust Zinc Finger DNA-binding protein (ZFP) technology**
 - ZFPs can be engineered to bind specific gene sequences
 - Gene Regulation (ZFP TFTM); Gene Modification (ZFNTM)



- **Focused on ZFP TherapeuticTM product development**
 - Diabetic neuropathy: (SB-509-601) Phase 2 complete, data ADA 06/09
 - Blocked nerve study: (SB-509-701) Phase 2 (Group A) completed, data ADA 06/09. Trial expanded (Group B) data 1H 2010
 - Stem cell mobilization: (SB-509-703) accrual and treatment completed
 - Amyotrophic Lateral Sclerosis (ALS): (SB-509-801) Phase 2 accrual complete
 - Infectious diseases (HIV/CCR5): (SB-728-T) Phase 1 initiated
 - Cancer (Glioblastoma): (SB-313) IND 2009
 - Cancer pain (TrkA, PN3)
 - Nerve regeneration (spinal cord injury, stroke)
 - Parkinson's disease (GDNF)
 - Monogenic diseases (hemoglobinopathies, X-linked SCID)
- **Milestones**
 - ADA June 2009
 - *SB-509-601*: Statistically significant improvement ($p=0.05$) in an analysis of multiple endpoints in subjects with more advanced disease <18 nerve fibers/mm in skin biopsies. Using baseline disease stratification (QST, sural NCV, NIS-LL) observed measurable improvements in NIS-LL
 - *SB-509-701*: Restoration of and clinically relevant improvements in NCV
 - HIV/CCR5 (SB-728-T) – Phase 1 initiated Q1 2009
 - Dow AgroSciences - plant agriculture – Nature publication 04/09, milestones, royalties, sublicense income
 - Sigma-Aldrich - ZFN-Targeted Genome Editing CompoZrTM reagents and transgenic animals– milestones, royalties
 - Cell line engineering collaborations – Genentech – double KO; PFE - \$3.0 M – one target, non-exclusive
- **Strong balance sheet**
 - 2Q09 cash ~ \$53 M / Cash through 2011
 - Successfully monetized technology - DAS / Sigma-Aldrich / Pfizer / Genentech / Roche
- **Preminent intellectual property and experienced management team**